Hepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting'
Despite a sharp decline in stock price, retail traders are optimistic about the company's potential, citing its core asset Rencofilstat and speculating on a rebound following the OTC transition.